The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Suresh S. Ramalingam

Department of Hematology and Medical Oncology

Winship Cancer Institute

Emory University




Name/email consistency: high



  • Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, USA. 2009 - 2012
  • Winship Cancer Institute, Emory University, 1365 Clifton Rd NE, Suite C-3090. 2010 - 2012
  • 1365 Clifton Rd NE, Rm C-3090, Atlanta, GA 30322;. 2011
  • Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, USA. 2008


  1. Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan-Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non-Small-Cell Lung Cancer. Ramalingam, S.S., Blackhall, F., Krzakowski, M., Barrios, C.H., Park, K., Bover, I., Seog Heo, D., Rosell, R., Talbot, D.C., Frank, R., Letrent, S.P., Ruiz-Garcia, A., Taylor, I., Liang, J.Q., Campbell, A.K., O'Connell, J., Boyer, M. J. Clin. Oncol. (2012) [Pubmed]
  2. Hypogonadism related to crizotinib therapy: Implications for patient care. Ramalingam, S.S., Shaw, A.T. Cancer (2012) [Pubmed]
  3. Bortezomib for patients with advanced-stage bronchioloalveolar carcinoma: a California Cancer Consortium Phase II study (NCI 7003). Ramalingam, S.S., Davies, A.M., Longmate, J., Edelman, M.J., Lara, P.N., Vokes, E.E., Villalona-Calero, M., Gitlitz, B., Reckamp, K., Salgia, R., Wright, J.J., Belani, C.P., Gandara, D.R. J. Thorac. Oncol (2011) [Pubmed]
  4. Randomized Phase II Study of Erlotinib in Combination With Placebo or R1507, a Monoclonal Antibody to Insulin-Like Growth Factor-1 Receptor, for Advanced-Stage Non-Small-Cell Lung Cancer. Ramalingam, S.S., Spigel, D.R., Chen, D., Steins, M.B., Engelman, J.A., Schneider, C.P., Novello, S., Eberhardt, W.E., Crino, L., Habben, K., Liu, L., Jänne, P.A., Brownstein, C.M., Reck, M. J. Clin. Oncol. (2011) [Pubmed]
  5. Cetuximab for the Treatment of Advanced Bronchioloalveolar Carcinoma (BAC): An Eastern Cooperative Oncology Group Phase II Study (ECOG 1504). Ramalingam, S.S., Lee, J.W., Belani, C.P., Aisner, S.C., Kolesar, J., Howe, C., Velasco, M.R., Schiller, J.H. J. Clin. Oncol. (2011) [Pubmed]
  6. Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097). Ramalingam, S.S., Belani, C.P., Mack, P.C., Vokes, E.E., Longmate, J., Govindan, R., Koczywas, M., Ivy, S.P., Gandara, D.R. J. Thorac. Oncol (2010) [Pubmed]
  7. Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. Ramalingam, S.S., Maitland, M.L., Frankel, P., Argiris, A.E., Koczywas, M., Gitlitz, B., Thomas, S., Espinoza-Delgado, I., Vokes, E.E., Gandara, D.R., Belani, C.P. J. Clin. Oncol. (2010) [Pubmed]
  8. Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study. Ramalingam, S.S., Kummar, S., Sarantopoulos, J., Shibata, S., LoRusso, P., Yerk, M., Holleran, J., Lin, Y., Beumer, J.H., Harvey, R.D., Ivy, S.P., Belani, C.P., Egorin, M.J. J. Clin. Oncol. (2010) [Pubmed]
  9. Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma. Ramalingam, S.S., Belani, C.P., Ruel, C., Frankel, P., Gitlitz, B., Koczywas, M., Espinoza-Delgado, I., Gandara, D. J. Thorac. Oncol (2009) [Pubmed]
  10. The role of the taxanes in the treatment of older patients with advanced stage non-small cell lung cancer. Ramalingam, S.S., Khuri, F.R. Oncologist (2009) [Pubmed]
  11. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. Ramalingam, S.S., Dahlberg, S.E., Langer, C.J., Gray, R., Belani, C.P., Brahmer, J.R., Sandler, A.B., Schiller, J.H., Johnson, D.H. J. Clin. Oncol. (2008) [Pubmed]
  12. A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies. Ramalingam, S.S., Egorin, M.J., Ramanathan, R.K., Remick, S.C., Sikorski, R.P., Lagattuta, T.F., Chatta, G.S., Friedland, D.M., Stoller, R.G., Potter, D.M., Ivy, S.P., Belani, C.P. Clin. Cancer Res. (2008) [Pubmed]
WikiGenes - Universities